



PRESS RELEASE

FOR RELEASE

June 2, 2014

**SAPHENEIA INC. COMPLETES INITIAL PHASE OF
RECAPITALIZATION**

DENVER, Colorado USA – June 2, 2014 – Sapheneia Inc., a global medical technologies company, has officially completed initial phase of its corporate recapitalization as the new parent company for worldwide product distribution. Sapheneia Inc. was formed in 2013 to position and equip the company for its next phase of growth.

Sapheneia Inc. executed an asset purchase agreement with its Swedish subsidiary Sapheneia Development AB to acquire key assets including intellectual property and worldwide day to day operations. Sapheneia Development AB is now solely a Research and Development facility with Dr. Hagen Spies being named as its Director.

Paul Stashick, Chief Executive Officer, said “We are indeed excited for the future and this recapitalization will enable the launch of several new software products”.

ABOUT SAPHENEIA INC.

Sapheneia Inc. is an American global technologies company that specializes in diagnostic and analytical image processing solutions, among other innovative products. The solutions provided by Sapheneia range from dose reduction services for X-Ray and CT to Original Equipment Manufacturer (OEM) Solutions for multi-modalities. It is the first and largest non-OEM company dedicated to radiation dose reduction through image quality enhancement at the lowest cost possible.

Sapheneia Inc. is not affiliated with any of the following companies that have been involved in litigation in Sweden: Sapheneia Global LLC, Sapheneia Commercial Products AB, and CATX Inc., These companies have ceased all business operations.

PRESS CONTACTS

Scott Chomiak, Sapheneia
Scott.chomiak@sapheneia.com